Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug’s profile.
You may also be interested in...
Settling In To The “New Normal”: Midway Through 2012, Another Banner Year For Drug Approvals Is Within Reach
The forecast for 2012 approvals looks sunny. FDA approved almost as many novel drugs in the first half of 2012 as it did in the first half of its record-breaking 2011 – and the agency has more than twice as many pending NME applications with user fee goals in the next six months as it had last year.
Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.
Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?
Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: